Organovo (NASDAQ:ONVO) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the medical research company’s stock.

Organovo Price Performance

ONVO stock opened at $0.37 on Friday. Organovo has a fifty-two week low of $0.32 and a fifty-two week high of $1.74. The firm’s 50-day simple moving average is $0.38 and its 200 day simple moving average is $0.44. The stock has a market cap of $6.44 million, a PE ratio of -0.43 and a beta of 0.54.

Organovo (NASDAQ:ONVO) last announced its earnings results on Wednesday, February 19th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.05 million. Organovo had a negative net margin of 10,151.64% and a negative return on equity of 346.26%. Equities analysts forecast that Organovo will post -0.77 EPS for the current fiscal year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.